imatinib has been researched along with Leukemia, Myelomonocytic, Chronic in 1 studies
Leukemia, Myelomonocytic, Chronic: A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pandey, A | 1 |
| Volkots, DL | 1 |
| Seroogy, JM | 1 |
| Rose, JW | 1 |
| Yu, JC | 1 |
| Lambing, JL | 1 |
| Hutchaleelaha, A | 1 |
| Hollenbach, SJ | 1 |
| Abe, K | 1 |
| Giese, NA | 1 |
| Scarborough, RM | 1 |
1 other study available for imatinib and Leukemia, Myelomonocytic, Chronic
| Article | Year |
|---|---|
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Topics: Administration, Oral; Animals; Biological Availability; Dogs; Enzyme Inhibitors; Female; fms-Like Ty | 2002 |